Published in N Engl J Med on November 01, 1990
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol (2012) 5.66
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) (2008) 2.50
Macrophage activation by endogenous danger signals. J Pathol (2008) 2.38
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 2.36
Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study. Am J Gastroenterol (2015) 2.35
DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol (2003) 2.22
Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe (2013) 2.22
Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut (2002) 2.21
The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 2.18
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut (2000) 2.17
Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut (1998) 2.14
Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut (2002) 2.13
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut (1994) 2.12
Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog (2009) 2.06
Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology (2011) 2.01
Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res (2009) 1.90
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A (2009) 1.81
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol (2008) 1.79
The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res (2008) 1.78
IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol (2010) 1.77
Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut (1994) 1.75
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol (2012) 1.63
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut (2004) 1.63
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology (2006) 1.62
Differential roles of the SPINK1 gene mutations in alcoholic and nonalcoholic chronic pancreatitis. J Gastroenterol (2007) 1.62
Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol (2011) 1.59
Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol (2013) 1.58
A hexane fraction of American ginseng suppresses mouse colitis and associated colon cancer: anti-inflammatory and proapoptotic mechanisms. Cancer Prev Res (Phila) (2012) 1.55
Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis (2011) 1.53
Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. Dig Dis Sci (2014) 1.51
Defective hMSH2/hMLH1 protein expression is seen infrequently in ulcerative colitis associated colorectal cancers. Gut (2000) 1.50
Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol (2009) 1.46
From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther (2008) 1.43
Meta-analyses of colorectal cancer risk factors. Cancer Causes Control (2013) 1.42
Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg (2004) 1.40
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39
Novel Synthetic Oxazines Target NF-κB in Colon Cancer In Vitro and Inflammatory Bowel Disease In Vivo. PLoS One (2016) 1.38
Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol (1999) 1.35
Dietary iron supplementation enhances DSS-induced colitis and associated colorectal carcinoma development in mice. Dig Dis Sci (2002) 1.34
Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal (2008) 1.33
Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol (2009) 1.33
Regulation of inflammation in cancer by eicosanoids. Prostaglandins Other Lipid Mediat (2011) 1.31
Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol (2008) 1.30
Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.28
General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut (1998) 1.26
Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res (2009) 1.25
Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer (2003) 1.25
Colorectal cancer surveillance in inflammatory bowel disease: the search continues. World J Gastroenterol (2009) 1.24
Increased risk of left sided colon cancer in patients with diverticular disease. Gut (1993) 1.24
Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol (2012) 1.21
Current management of inflammatory bowel disease and colorectal cancer. Gastrointest Cancer Res (2011) 1.21
Microbial induction of immunity, inflammation, and cancer. Front Physiol (2011) 1.20
Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. Int J Colorectal Dis (2008) 1.19
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
MicroRNAs in inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.19
Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol (2011) 1.19
Incidence of colorectal cancer and all cause mortality in non-selected patients with ulcerative colitis and indeterminate colitis in Malmö, Sweden. Int J Colorectal Dis (1995) 1.18
Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol (2014) 1.16
Ileal pouch surgery for ulcerative colitis. World J Gastroenterol (2007) 1.15
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology (2009) 1.15
Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut (1991) 1.15
Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res (2012) 1.13
Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer (2005) 1.13
Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg (2008) 1.12
Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis (2009) 1.10
Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr (2012) 1.10
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
Genetic instability and the mutator phenotype. Studies in ulcerative colitis. Am J Pathol (1999) 1.08
Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut (2004) 1.08
Dietary selenium deficiency exacerbates DSS-induced epithelial injury and AOM/DSS-induced tumorigenesis. PLoS One (2013) 1.07
Infection, inflammation, and gastrointestinal cancer. Gut (2005) 1.07
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J Clin Invest (1994) 1.07
The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ (2013) 1.06
Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer (2015) 1.05
The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis (2007) 1.04
A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia. Pharmacogenomics J (2008) 1.04
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03
mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest (2013) 1.03
Immune chaperone gp96 drives the contributions of macrophages to inflammatory colon tumorigenesis. Cancer Res (2013) 1.02
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in Mice. Gastroenterology (2015) 1.01
C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer. World J Gastroenterol (2004) 1.01
Modeling colitis-associated cancer with azoxymethane (AOM) and dextran sulfate sodium (DSS). J Vis Exp (2012) 1.01
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. Inflamm Bowel Dis (2011) 1.01
IL-22 is related to development of human colon cancer by activation of STAT3. BMC Cancer (2013) 1.01
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol (2000) 4.83
The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med (1996) 4.81
Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst (1993) 4.59
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
Evidence of prenatal influences on breast cancer risk. Lancet (1992) 4.25
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
Transient increase in the risk of breast cancer after giving birth. N Engl J Med (1994) 4.08
Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05
Infections as a major preventable cause of human cancer. J Intern Med (2000) 3.96
Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80
Cohort studies of fat intake and the risk of breast cancer--a pooled analysis. N Engl J Med (1996) 3.79
The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med (1989) 3.77
Stressful life events and Graves' disease. Lancet (1991) 3.63
Should the mission of epidemiology include the eradication of poverty? Lancet (1998) 3.42
Effect of low-level body burdens of lead on the mental development of children: limitations of meta-analysis in a review of longitudinal data. Arch Environ Health (1992) 3.42
Intake of fruits and vegetables and risk of breast cancer: a pooled analysis of cohort studies. JAMA (2001) 3.37
Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden. BMJ (1998) 3.34
Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst (1998) 3.10
Overweight as an avoidable cause of cancer in Europe. Int J Cancer (2001) 2.88
Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst (1994) 2.81
Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet (2000) 2.75
Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst (1996) 2.71
Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 2.69
Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet (2000) 2.65
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer (1990) 2.61
Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet (1990) 2.58
International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control (1997) 2.52
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology (1991) 2.51
Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial. Lancet (1983) 2.51
Maternal pregnancy hormone levels in an area with a high incidence (Boston, USA) and in an area with a low incidence (Shanghai, China) of breast cancer. Br J Cancer (1999) 2.31
Natural history of cervical neoplasia: consistent results obtained by an identification technique. Br J Cancer (1989) 2.30
Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. J Natl Cancer Inst (1996) 2.29
Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. J Natl Cancer Inst (1990) 2.22
Survival in breast cancer diagnosed between mammographic screening examinations. Lancet (1986) 2.12
Perinatal measles infection and subsequent Crohn's disease. Lancet (1994) 2.11
Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol (1989) 2.07
Risk of urinary tract cancers following kidney or ureter stones. J Natl Cancer Inst (1997) 2.06
Response rate to mailed epidemiologic questionnaires: a population-based randomized trial of variations in design and mailing routines. Am J Epidemiol (1998) 2.06
[Meta-analysis is a good help for literature review. It makes the analysis of earlier studies more efficient and more objective]. Lakartidningen (1999) 2.02
Pesticides and cancer. Cancer Causes Control (1997) 2.00
Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst (1997) 1.98
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer (1999) 1.98
Detection of preinvasive cancer of the cervix and the subsequent reduction in invasive cancer. J Natl Cancer Inst (1993) 1.87
Acute subjective and physiological responses to smoking in adolescents. Addiction (2001) 1.87
Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer (1998) 1.86
Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med (2000) 1.83
Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet (1986) 1.79
Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med (1986) 1.79
Country profile: Sweden. Lancet (1996) 1.76
Risk factors for oesophageal cancer in northeast China. Int J Cancer (1994) 1.73
Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst (1999) 1.73
Smoking and colorectal cancer: a 20-year follow-up study of Swedish construction workers. J Natl Cancer Inst (1996) 1.71
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer (1997) 1.69
Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst (1997) 1.68
Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer (2000) 1.67
Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology (1992) 1.65
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology (1994) 1.64
Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. Cancer Res (1999) 1.63
Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst (1995) 1.62
Twin membership and breast cancer risk. Am J Epidemiol (1992) 1.62
Time trends in incidence rates of first hip fracture in the Uppsala Health Care Region, Sweden, 1965-1983. Am J Epidemiol (1989) 1.62
Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control (2000) 1.61
Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979. Surgery (1987) 1.56
Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer (1999) 1.55
Maternal and perinatal risk factors for childhood leukemia. Cancer Res (1991) 1.55
Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst (1995) 1.53
International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer (1997) 1.50
Gender of offspring and maternal breast cancer risk. Int J Cancer (1999) 1.50
Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst (1994) 1.49
Types of dietary fat and breast cancer: a pooled analysis of cohort studies. Int J Cancer (2001) 1.48
Extracolonic malignancies in inflammatory bowel disease. Cancer (1991) 1.47
Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer (1993) 1.46
The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia (1999) 1.45
Relationship between age and survival in cancer of the colon and rectum with special reference to patients less than 40 years of age. Br J Surg (1990) 1.45
Testicular nonseminoma and seminoma in relation to perinatal characteristics. J Natl Cancer Inst (1996) 1.44
Survival and renal function in untreated hypercalcaemia. Population-based cohort study with 14 years of follow-up. Lancet (1987) 1.42
Does age at the last birth affect breast cancer risk? Eur J Cancer (1996) 1.42
Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer (1997) 1.42
Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control (1999) 1.42
Re: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol (1996) 1.41
Serum concentrations of organochlorines in men: a search for markers of exposure. Sci Total Environ (2000) 1.40
Melanoma in pregnancy. Lancet (1991) 1.39
Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat (1996) 1.39
Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ (1989) 1.39